GlassScriptPhysician profile
Jerry D Fan
NPI 1619405784
$37,178.33
in general payments reported to CMS, 2019-2025
43 companies · $8,149 in 2025
The $8,149 reported for 2025 was more than what 94% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,911 · 2020: $2,347 · 2021: $2,964 · 2022: $6,220 · 2023: $6,886 · 2024: $7,701 · 2025: $8,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $7,074 · Travel and Lodging: $4,733 · Education: $369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,561.26 |
| Consulting Fee | $7,074.00 |
| Travel and Lodging | $4,732.52 |
| Education | $368.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $6,772.39 | 2022-2025 | Ensite Precision, Assurity, Thoratec Heartmate 3 Lvas Implant Kit |
| Astrazeneca Pharmaceuticals LP | $4,830.26 | 2019-2025 | Lokelma, Farxiga, Imfinzi |
| Amgen INC. | $4,708.80 | 2023-2025 | Repatha, Repatha |
| Abiomed | $2,659.65 | 2022-2025 | Impella |
| Medtronic, INC. | $2,346.02 | 2021-2025 | Corevalve Evolut R, Symplicity G3, Onyx Frontier |
| Novartis Pharmaceuticals Corporation | $1,944.12 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,798.14 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $1,519.75 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $1,289.52 | 2020-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $1,112.88 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Vifor Pharma, INC. | $960.11 | 2020-2024 | Veltassa, Korsuva |
| Pfizer INC. | $754.40 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $653.29 | 2022-2025 | Amvuttra, Onpattro |
| Alexion Pharmaceuticals, INC. | $628.91 | 2019-2023 | |
| Paratek Pharmaceuticals, INC. | $476.89 | 2020-2024 | Nuzyra |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $456.89 | 2020-2025 | Jardiance |
| Abbvie INC. | $425.29 | 2019-2025 | |
| Portola Pharmaceuticals, LLC | $415.86 | 2019-2020 | |
| Allergan, INC. | $390.83 | 2019-2020 | |
| Inari Medical, INC. | $342.65 | 2020-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Melinta Therapeutics, LLC | $333.84 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $318.44 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $253.90 | 2019-2024 | Verquvo, Dificid, Zerbaxa |
| Lantheus Medical Imaging, INC. | $241.60 | 2022-2024 | Definity |
| Cardiva Medical, INC. | $205.31 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Janssen Scientific Affairs, LLC | $188.08 | 2021-2025 | Rybrevant |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.86 | 2020-2023 | Xifaxan |
| Heartflow, INC. | $141.56 | 2023 | Ffrct |
| Esperion Therapeutics, INC. | $140.62 | 2020-2025 | Nexletol |
| Edwards Lifesciences Corporation | $137.21 | 2022 | |
| Cmp Pharma, INC. | $101.63 | 2022 | |
| Shionogi INC | $63.26 | 2021-2023 | Fetroja |
| Chiesi USA, INC. | $53.88 | 2020-2021 | |
| Boston Scientific Corporation | $47.84 | 2022-2024 | Watchman Flx |
| Teleflex LLC | $44.59 | 2023-2024 | Trapliner, Bandit |
| Pharmacosmos Therapeutics INC. | $44.38 | 2020-2021 | |
| Biogen, INC. | $43.69 | 2021 | |
| Dexcom, INC. | $34.83 | 2022-2023 | Dexcom G6 Transmitter |
| Cardiovascular Systems INC. | $34.34 | 2022 | |
| Ferring Pharmaceuticals INC. | $33.91 | 2022-2023 | Rebyota |
| Aurinia Pharma U.S., INC. | $22.17 | 2023 | Lupkynis |
| Astellas Pharma US INC | $21.58 | 2020 | |
| Bioxcel Therapeutics, INC. | $21.16 | 2023 | Igalmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Fan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.